Health CarePharmaceuticals and Biotechnology
  • Price (USD)97.96
  • Today's Change-2.80 / -2.78%
  • Shares traded1.06m
  • 1 Year change-2.37%
  • Beta1.4049
Data delayed at least 15 minutes, as of May 18 2022 20:58 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Catalent, Inc. provides delivery technologies, and development and manufacturing solutions for drugs; protein, cell, and gene therapy biologics; and consumer health products. Its segments include Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment is engaged in providing formulation, development, and manufacturing services for soft capsules, as well as largescale manufacturing of oral solid dose forms. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing services. The Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is engaged in manufacturing, packaging, distribution and inventory management for drugs and biologics in clinical trials.

  • Revenue in USD (TTM)4.70bn
  • Net income in USD486.90m
  • Incorporated2007
  • Employees17.30k
  • Location
    Catalent Inc14 Schoolhouse RdSOMERSET 08873-1213United StatesUSA
  • Phone+1 (732) 537-6200
  • Fax+1 (732) 537-6480
  • Websitehttps://www.catalent.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
CTLT:NYQ since
The Vaccine Manufacturing & Innovation CentreDeal completed18 Feb 202218 Feb 2022Deal completed-0.01%--
Bettera Holdings LLCAnnounced30 Aug 202130 Aug 2021Announced-24.56%1.00bn
Rheincell Therapeutics GmbHAnnounced24 Jun 202124 Jun 2021Announced-10.20%--
Data delayed at least 15 minutes, as of May 18 2022 20:58 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Charles River Laboratories Intl. Inc3.63bn422.47m11.98bn18.60k28.734.5916.893.308.218.2170.5351.380.563410.935.55195,135.606.686.617.827.8537.5637.1511.8510.931.1212.480.50080.0021.0816.067.3220.4132.85--
Viatris Inc17.65bn167.70m13.43bn37.00k80.950.65693.370.76120.13690.136914.5716.870.31392.454.74476,964.900.2983-0.36850.3613-0.442839.2538.970.9503-1.170.82413.960.5184--49.7310.06-89.45---7.46--
BioMarin Pharmaceutical Inc.1.88bn35.43m14.38bn3.05k505.823.27100.697.650.15370.17510.0623.750.31680.6234.55617,275.600.597-0.9720.6472-1.1275.1476.741.88-2.913.28-18.930.1974---0.762210.58-1,590.90---4.28--
BIO-TECHNE Corp1.08bn225.38m14.43bn2.60k67.098.4245.7013.405.485.4826.2043.660.4912.895.98413,999.609.847.2410.607.7068.0166.7520.0517.662.79--0.131338.2426.0413.28-38.746.0821.260.00
Cardinal Health Inc176.85bn-955.00m15.15bn47.30k------0.0857-3.55-3.55621.06-2.554.1111.4318.643,738,837.00-2.22-0.5466-5.97-1.293.634.70-0.5395-0.1510.5369.651.14--6.245.98116.53-15.60-2.974.66
Alnylam Pharmaceuticals, Inc.879.98m-892.87m15.28bn1.67k--38.06--17.36-7.48-7.487.383.320.26311.907.84528,516.50-26.70-32.56-31.96-37.9483.56---101.47-223.644.14-3.230.6278--71.3178.070.6358--3.42--
Incyte Corporation3.11bn933.04m16.59bn2.09k17.834.2916.705.334.204.2014.0117.450.71485.486.491,487,480.0021.415.8925.907.0595.4195.8829.967.983.6714.400.00880.0011.9821.98420.8055.538.52--
ICON PLC6.52bn168.03m17.15bn38.33k84.622.1328.132.632.492.4987.0699.260.6325--4.18170,216.301.657.222.019.5327.6130.262.629.57--2.980.3892--95.9326.88-53.91-10.1917.09--
Catalent Inc4.70bn486.90m17.60bn17.30k35.353.7921.003.742.782.7826.8225.880.49274.974.14271,861.305.384.206.074.7833.8332.1410.928.332.235.280.47470.0029.2116.69205.7836.5337.50--
Gartner Inc4.89bn801.98m20.58bn16.60k27.00175.7020.454.219.469.4657.861.450.7028--3.85294,738.8011.524.1220.437.0669.6165.0016.396.65--10.740.9542--15.4814.13197.5032.603.71--
Horizon Therapeutics PLC3.77bn862.10m20.79bn1.94k24.774.3116.765.523.653.6515.9720.990.45453.916.681,994,312.0010.393.9311.504.6475.8871.3722.8710.983.3011.860.34780.0046.6326.8837.12--37.25--
Data as of May 18 2022. Currency figures normalised to Catalent Inc's reporting currency: US Dollar USD

Institutional shareholders

51.83%Per cent of shares held by top holders
HolderShares% Held
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 202118.62m10.39%
The Vanguard Group, Inc.as of 31 Mar 202218.28m10.20%
Capital Research & Management Co. (World Investors)as of 31 Dec 202110.50m5.86%
BlackRock Fund Advisorsas of 31 Mar 20229.27m5.17%
Janus Henderson Investors US LLCas of 31 Dec 20218.81m4.92%
Veritas Asset Management LLPas of 31 Mar 20227.00m3.91%
SSgA Funds Management, Inc.as of 31 Dec 20216.86m3.83%
Franklin Advisers, Inc.as of 31 Mar 20225.80m3.23%
Artisan Partners LPas of 31 Mar 20224.35m2.43%
Geode Capital Management LLCas of 31 Mar 20223.41m1.90%
More ▼
Data from 31 Dec 2021 - 31 Mar 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.